Work

Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

Year: 2025

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2025.2499720

Authors: Yueyang Huang, Hongmei Yuan, Zhe Huang, Zhe Huang

Institution: Shenyang Pharmaceutical University

Language: English

Topic: Neurogenetic and Muscular Disorders Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410144148

FWCI: 0.527

Cites: 65

Cited by: 1

Related to: 10